Regulatory update: Votrient® (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has withdrawn its application to the European Medicines Agency (EMA) for a variation to the Marketing Authorisation for Votrient® (pazopanib).
Source: GSK news - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Marketing | Ovarian Cancer | Ovaries | Pharmaceuticals